Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 603 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Opioid Use Disorder, Opioid Dependence, Chronic Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of the Supraspinal Opioidergic Circuit in Prefrontal TMS-Induced Analgesia

NCT01643798
Conditions
Pain
Interventions
Sham rTMS, Real rTMS
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Substance-related Disorders, HIV Risk Behavior
Interventions
Therapeutic Workplace, Methadone, Buprenorphine
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alcoholism
Interventions
Naltrexone 50 Mg, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

Integrative Psychosocial Group Treatment

NCT03648177
Conditions
Chronic Pain, Opioid Misuse
Interventions
IPGT, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Alcoholism, Depression
Interventions
naltrexone (Revia), sertraline (Zoloft), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder

NCT02669901
Conditions
Opiate Antagonist Overdose, Opioid-Related Disorders
Interventions
Naloxone Auto-Injector
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Alcohol Dependence
Interventions
Naltrexone 50 Mg, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Charleston, South Carolina
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Naltrexone for Overdose Prevention

NCT06633900
Conditions
Overdose Accidental
Interventions
IM naltrexone, Usual Care
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2Phase 3 Interventional Results available

Cocaine Use Reduction With Buprenorphine

NCT01402492
Conditions
Cocaine Dependence
Interventions
Buprenorphine + Naltrexone, Placebo + Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Conditions
Alcoholism
Interventions
naltrexone (Revia), Compliance Enhancement Tech., Cognitive Behavior Therapy
Drug · Behavioral
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Pain
Interventions
buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Conditions
Cocaine-Related Disorders
Interventions
Naltrexone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1996
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Opioid-Related Disorders
Interventions
Naltrexone
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1998
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Phase 2 Interventional

LIFT: Life Improvement Trial

NCT06366724
Conditions
ME/CFS, Long COVID, PASC
Interventions
Pyridostigmine, Low-Dose Naltrexone, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Opiate Dependence, Heroin Dependence
Interventions
depot naltrexone, Oral Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Induction for Fentanyl Dependent Opioid Users

NCT04794790
Conditions
Opioid Dependence Fentanyl
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Completed Not applicable Interventional Results available

SMART Effectiveness Trial

NCT04464421
Conditions
Opioid-use Disorder, Opioid Dependence, Treatment Adherence
Interventions
Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction & Methadone & Buprenorphine

NCT02045693
Conditions
Hepatitis C
Interventions
Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah